{"analyses":[{"groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY","pValue":"<.0001","statisticalMethod":"Fisher Exact"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1"},{"groupId":"OG001","value":"42.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"196"},{"groupId":"OG001","value":"195"}],"units":"Participants"}],"description":"Overall Response Rate per the IWCLL 2008 criteria as assessed by IRC, limited to the time of primary analysis 06 November 2013","groups":[{"description":"An anti-CD20 monoclonal antibody\n\nofatumumab: The ofatumumab (IV) dosage and schedule is 12 doses administered over 24 weeks or until disease progression, unacceptable toxicity.\n\nWeek 1: 300 mg initial dose Week 2 through 8: 2,000 mg (once weekly) Week 12, 16, 20 and 24: 2,000 mg (every 4 weeks)","id":"OG000","title":"Ofatumumab (Arm A)"},{"description":"A Bruton Tyrosine Kinase Inhibitor\n\nibrutinib: ibrutinib 420 mg (3 x 140-mg capsules) will be administered orally once daily until disease progression or unacceptable toxicity","id":"OG001","title":"Ibrutinib (Arm B)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"About 18 months after the first subject was enrolled","title":"Overall Response Rate (ORR) by Independent Review Committee (IRC)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}